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The discovery and development of new medicines occupies years of painstaking and expensive 
scientific work, with multidisciplinary teams working together in the hope of developing a new 
chemical entity that outperforms the current standard of care within the chosen disease setting. 
Once optimised in the laboratory and achieving acceptable regulatory pre-clinical benchmarks, 
years of clinical evaluation are required to persuade the regulatory authorities of a Ŷeǁ ageŶt͛s 
superior efficacy in order to license a new medicine. In short, drug discovery is a high-risk and 
expensive business [1], with most drug candidates failing (ideally early) along the development 
pathway and the full cost of new drug development from ͛bench to bedside͛ averaging out at an 
estimated $2.6 billion [2]. On the other hand, the rewards available to those companies with the 
global reach and resources to launch a new drug are considerable. Drug market dynamics partly 
explain why new branded products tend to be expensive (pitched at a price that the market can 
sustain), with market exclusivity protected by patent filings. It also partly explains why there is 
relatively little progress in areas of unmet medical need where patients and their healthcare 
systems simply cannot afford to pay high prices for new medicines, such as certain tropical 
infectious diseases. 
Despite the perverse incentives towards chronic disease with large market potential, new 
medicine discovery as outlined above is generally regarded as the acceptable face of drug 
development. 
In a previous editorial [3] we outlined the development of new psychoactive substances, 
often seen as the dark side or unacceptable face of medicinal chemistry and drug discovery. 
Within this market, there is little scientific rigour, and no painstaking attention to pharmaceutical 
quality control, or indeed toxicity testing to protect the welfare of the consumer [4]. On the other 
hand, it is notable that amongst the bewildering array of new psychoactive substances consumed, 
many are analogues or close relatives of compounds originally discovered within pharmaceutical 
industry laboratories for potential treatment of CNS disorders. 
In this perspective, we highlight the emergence of two drugs (Figure 1) with a bad 
reputation – MDMA (ecstasy) and the prodrug psilocybin (from psilocybe mushrooms) – in the 
effective treatment of psychological disorders and their possible future availability within a 
healthcare context. These two selected examples, snapshots of growing activity in this field, serve 
to highlight the often-cited need for a grown-up and informed debate around use of scheduled 
(controlled) drugs. 
 
 
 
Figure 1. Chemical structures of MDMA (ecstasy) and psilocybin. 
 
3,4-Methylenedioxymethamphetamine (MDMA; ecstasy; Molly) is a stimulant psychoactive drug 
commonly used in a recreational setting [4,5]. In most countries MDMA is illegal as a consequence 
of its stimulant, empathogenic and entactogenic properties, popularity as a party drug, and 
occasional reported fatal overdose. The unregulated market around this illegal drug means that 
MDMA is sold in varying doses and often adulterated with other substances such as ephedrine 
and paramethoxyamphetamine [4]. Remarkably it was estimated that around 22 million people 
worldwide used ecstasy in 2015, according to the UN World Drug Report [101]. Due to the 
numbers of users of MDMA worldwide, and comparative safety of pharmaceutical quality MDMA 
at low doses, there may be a future for MDMA to be sold in a healthcare setting for reducing the 
harms caused by recreational drugs such as black market ecstasy and new psychoactive 
substances [6]. 
MDMA has a range of effects including modulation of the serotonergic and noradrenergic 
systems; and  induces release of the social bonding hormone oxytocin by binding to 5-HT1A 
receptors on hypothalamic oxytocin-containing neurons. [7,8]. The effects of increased openness 
and empathy are reported as being a major component of the therapeutic effect of MDMA in 
psychotherapy and its continued recreational use [9]. 
MDMA has been used as an adjunct to psychotherapy since the 1970s, when it was used 
as an alternative to MDA in psychotherapy sessions after MDA was made illegal in 1970 [10]. The 
synthesis and studies into the psychoactive effects of MDMA were conducted by Alexander 
Shulgin and his wife Ann Shulgin who conducted further research iŶto MDMA͛s poteŶtial uses in 
psychotherapy [10]. MDMA started to be used by psychotherapists as an effective aid to 
treatment until the drug͛s sĐheduliŶg ďǇ the US Drug Enforcement Agency pushed MDMA-
assisted psychotherapy underground in the 1980s. Recently, phase III clinical trials into MDMA-
assisted psychotherapy have been approved after successful completion of phase II studies for 
ex-military personnel, firefighters and police officers with post-traumatic stress disorder [11]. 
The chemical structure of psilocybin (Figure 1) is related to serotonin. Extensive research 
has suggested that after psilocybin has been metabolised (via dephosphorylation) to the 
pharmacologically active molecule psilocin, it mediates effects on the G protein-coupled 5-HT2A 
serotonin receptors [12,13]. Agonism of 5-HT2A receptors has effects on neuroplasticity, 
environmental sensitivity, learning and psychological adaptability [8]. 
Psilocybin has been studied for a range of conditions including alcohol [14] and tobacco 
[15] addiction, depression [16] and existential anxiety associated with life-threatening illness [17]. 
Recent studies have suggested that the mystical-type experience sometimes associated with 
psilocybin experiences has been correlated with therapeutic effects and a long-term increase in 
openness [17]. The results of these recent studies show psilocybin can, through the mystical 
experience, promote enduring changes in personality traits, priorities/values and improve 
emotional regulation. These observations suggest that psilocybin-assisted psychotherapy could 
have a positive effect on a societal level and may ultimately become an important component of 
mainstream Western medicine. 
Lesser known, potentially beneficial applications of psilocybin could be described as being 
in the field of positive psychology. The current medical paradigm consists of attempting to bring 
individuals from a poor state of mental health to acceptable or good mental health. There is little 
provision for attempting to ĐhaŶge a persoŶ͛s ŵeŶtal outlook froŵ the baseline state to excellent. 
Psychotherapeutic interventions typically only take place once a person has become mentally ill. 
We propose that psilocybin could be used as a preventative therapy in order to decrease the 
likelihood of at risk individuals developing poor mental health and to increase positive mental 
outlook. Usage of psilocybin has been associated with reduced likelihood of engaging in antisocial 
criminal behaviours [18], an enhanced appreciation for nature [19,20] and a decrease in sympathy 
for politically authoritarian perspectives [20]. In light of the benevolent changes in personality 
that can arise from the usage of psilocybin, it could be argued that responsible usage of psilocybin 
in therapeutic settings based on rigorous scientific evidence could assist in socio-environmental 
challenges such as climate change and interpersonal violence. 
It has been shown that, when members of the public are presented with contemporary 
information on relative harm and potential therapeutic applications, there is public support for 
these substances to be available in a healthcare setting particularly amongst the university-
educated section of the population [6]. Public and mainstream scientific perceptions of these 
substances are shifting and it is not difficult to envision a future in which MDMA and psilocybin 
play a role in contemporary medicine.  
One important consequence of the prevailing trend towards making psychoactive 
substances illegal in many countries is that research into the potential therapeutic benefits of 
these substances is severely curtailed. It has long been known that banning substances does not 
stop or even reduce psychoactive drug consumption [3]. In the internet age, and with the advent 
of the dark web, substance prohibition simply changes the nature of the supply chains, driving 
illicit production of more potent and harŵful suďstaŶĐes to the detriŵeŶt of the ĐoŶsuŵer͛s 
mental and physical health. For example, the 2016 U.K. Psychoactive Substances Bill [102] 
exemplifies the consequences of government policy being driven by mainstream media opinion 
rather than evidence-based science. The recent unintended rise of potent and harmful synthetic 
cannabinoids such as ͛Spice͛, particularly amongst the most vulnerable populations, provides one 
example amongst many of the consequences of ill-informed and reactionary policy making in the 
U.K. Meanwhile tobacco [103] and alcohol [104] consumption continue unabated in many 
countries, despite being responsible for more morbidity and mortality than all other illicit 
products combined [6].  
We repeat our previous call [3] for an evidence-based, scientifically informed debate 
around psychoactive substances, especially where there is evidence for positive benefit to treat 
rising incidence of mental health and CNS disorders. A vast array of psychoactive substances exist, 
with potential positive and negative effects for the consumer. Without the ability to carry out 
rigorous and objective research unimpeded, we will surely miss the opportunity to use 
psychoactive substances for the benefit of patients suffering from a whole range of disorders. 
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